The biopharma sector spent much of 2023 bracing for investor confidence to hit rock bottom. Come October, it felt like these fears had been realised. In 2024, however, are we seeing hints of an upturn? With global interest rates seemingly maxing out – a critical factor for this cash-hungry sector – the tide may be starting to turn. Caution remains the watchword, though: the economic landscape is still shaky at best and a smooth, swift recovery remains a long shot.
Gather insights on the below:
- The drugs and companies driving top line growth
- Hotly anticipated launches
- Major players in R&D investment
- Likely FDA approvals
- Money, markets and M&A
